Pharmacological management of ocular hypertension: current approaches and future prospective
- 28 February 2013
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 13 (1), 50-55
- https://doi.org/10.1016/j.coph.2012.09.012
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Pharmacological and therapeutic effects of A3 adenosine receptor agonistsDrug Discovery Today, 2011
- Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouseNeuroscience Letters, 2011
- Mechanisms of ATP Release, the Enabling Step in Purinergic DynamicsCellular Physiology and Biochemistry, 2011
- Development of a Gene Therapy Virus with a Glucocorticoid-Inducible MMP1 for the Treatment of Steroid GlaucomaInvestigative Opthalmology & Visual Science, 2010
- Episcleral Venous Pressure Responses to Topical Nitroprusside andN-Nitro-l-arginine Methyl EsterInvestigative Opthalmology & Visual Science, 2010
- Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across speciesExperimental Eye Research, 2009
- Update on the Mechanism of Action of Topical Prostaglandins for Intraocular Pressure ReductionSurvey of Ophthalmology, 2008
- Topical WIN55212-2 Alleviates Intraocular Hypertension in Rats Through a CB1 Receptor Mediated Mechanism of ActionJournal of Ocular Pharmacology and Therapeutics, 2008
- Prostamides (prostaglandin‐ethanolamides) and their pharmacologyBritish Journal of Pharmacology, 2008
- Agonist‐dependent cannabinoid receptor signalling in human trabecular meshwork cellsBritish Journal of Pharmacology, 2007